Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.

S'inscrire

EBS Emergent Biosolutions Inc

10,46

0,00 (0,00%)

Avant marché

Dernière mise à jour : 13:00:00

Retardé de 15 minutes

Form 144 - Report of proposed sale of securities

="/Images/box-checked.jpg" alt="Checkbox checked">

144: Remarks and Signature

Remarks

Date of Notice

11/11/2024

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

/s/ Martin Lamar White

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

Emergent Biosolutions (NYSE:EBS)
Graphique Historique de l'Action
De Jan 2025 à Fév 2025

Plus de graphiques de la Bourse Emergent Biosolutions

Emergent Biosolutions (NYSE:EBS)
Graphique Historique de l'Action
De Fév 2024 à Fév 2025

Plus de graphiques de la Bourse Emergent Biosolutions

Actualités Emergent Biosolutions Inc

Enrollment Starts in Africa CDC-Led MpOx Therapeutic Study (MOSA)
Jeudi 16 Janvier 2025 ( il y a 3 semaines) • GlobeNewswire Inc.

Form 8-K - Current report
Mercredi 15 Janvier 2025 ( il y a 3 semaines) • Edgar (US Regulatory)

Form 8-K - Current report
Mardi 14 Janvier 2025 ( il y a 3 semaines) • Edgar (US Regulatory)

Emergent BioSolutions Gains Exclusive Commercial Rights to KLOXXADO® (naloxone HCI) Nasal Spray from Hikma Pharmaceuticals
Mardi 14 Janvier 2025 ( il y a 3 semaines) • GlobeNewswire Inc.

Emergent BioSolutions Receives Contract Option Valued at Approximately $16.7 Million to Continue Development Collaboration with BARDA on Ebanga™ (ansuvimab-zykl) Treatment for Ebola
Lundi 13 Janvier 2025 ( il y a 4 semaines) • GlobeNewswire Inc.

Form 8-K - Current report
Mercredi 8 Janvier 2025 ( il y a 4 semaines) • Edgar (US Regulatory)

Emergent BioSolutions to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025
Mercredi 8 Janvier 2025 ( il y a 4 semaines) • GlobeNewswire Inc.

Emergent BioSolutions Announces Exercise of $20 Million Option to Supply U.S. Department of Defense with BioThrax® (Anthrax Vaccine Adsorbed)
Mercredi 8 Janvier 2025 ( il y a 1 mois) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Mardi 17 Décembre 2024 ( il y a 2 mois) • Edgar (US Regulatory)

Emergent BioSolutions Receives $50 Million Contract Option from BARDA to Procure Doses of CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted)
Lundi 16 Décembre 2024 ( il y a 2 mois) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Mardi 10 Décembre 2024 ( il y a 2 mois) • Edgar (US Regulatory)

Form EFFECT - Notice of Effectiveness
Jeudi 5 Décembre 2024 ( il y a 2 mois) • Edgar (US Regulatory)

Plus d'articles sur Emergent Biosolutions Inc

Societe Generale

Delayed Upgrade Clock

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales